SCHEMBL13629428

SCHEMBL13629428

CCc1ccc(NS(=O)(=O)c2ccc(C#N)cc2Cl)cc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 6/20 0.48
BRPF1 P55201 5/20 0.46
BRD1 O95696 2/20 0.46
BRPF3 Q9ULD4 2/20 0.46
TRIM24 O15164 1/20 0.43
BRD4 O60885 1/20 0.43
BRD9 Q9H8M2 1/20 0.43
BRD7 Q9NPI1 1/20 0.43
PIK3C3 Q8NEB9 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SMARCA2 P51531 1/20 0.42
TRPV4 Q9HBA0 1/20 0.42
SGK1 O00141 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CDK7 P50613 1/20 0.41
CCNH P51946 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629466 0.87 BRPF1 (0.46) SLC22A12BRPF1BRD1BRPF3PIK3C3
SCHEMBL13615230 0.83 SLC22A12 (0.48) SLC22A12BRPF1BRD1BRPF3TRIM24
SCHEMBL13629339 0.81 BRD4 (0.51) BRD4LMNASMN1; SMN2SGK1CDK1
SCHEMBL13629320 0.80 SLC22A12 (0.54) SLC22A12BRD4LMNA
SCHEMBL13629322 0.79 CDK1 (0.51) PIK3C3LMNASGK1CDK1CCNB1
SCHEMBL16325840 0.78 SLC22A12 (0.47) SLC22A12BRPF1BRD1BRPF3BRD4
SCHEMBL94461 0.77 SLC22A12 (0.48) SLC22A12PIK3C3LMNAPPARG
SCHEMBL13629329 0.76 ALDH1A1 (0.65) LMNASMN1; SMN2CDK1CCNB1CCNA2
SCHEMBL13615237 0.75 SLC22A12 (0.47) SLC22A12BRPF1BRD1BRPF3TRPV4
SCHEMBL13629401 0.75 ALDH1A1 (0.65) SLC22A12BRD4LMNACDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK SLC22A12 4627/4885BRPF1 3189/4885BRD1 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.